- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07946536
A Clinical Trial to Evaluate the Effects of Glow Shakes Premium Collagen Meal Replacement on Nutritional Adequacy, Body Composition, Skin Health, Satiety, and Overall Wellness in Adults Using GLP-1 or Dual-Incretin Medications for Weight Management
This is a single-group, open-label, decentralized clinical trial evaluating the effects of 12 weeks of once-daily consumption of Glow Shakes Premium Collagen Meal Replacement on nutritional adequacy, body composition, skin health, satiety, and overall wellness in 40 adults aged 18-55 years who are currently using a GLP-1 receptor agonist or dual-incretin medication for weight management. All study activities are conducted remotely; participants complete questionnaire assessments and smart scale body composition measurements at home at Baseline, Week 4, Week 8, and Week 12.
Participants replace a typical meal once daily with the study product for 12 consecutive weeks while continuing their existing GLP-1 or dual-incretin medication. The primary objective is to evaluate within-participant change in perceived nutritional adequacy from Baseline to Week 12. Secondary objectives include changes in body fat percentage, muscle mass, perceived skin health, hunger and satiety, hair health, energy and cognitive focus, nail health, gut comfort, metabolism support, physical strength, and product tolerability and satisfaction.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Izaak Woodley
- E-mail: izaakwoodley@thecollagen.co
Studie Locaties
-
-
Nevada
-
Las Vegas, Nevada, Verenigde Staten, 89101
- Citruslabs
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Adults aged 18-55 years at the time of enrollment.
- Currently using a GLP-1 receptor agonist or dual-incretin medication for weight management (e.g., semaglutide, tirzepatide, liraglutide) for a minimum of 4 weeks at the time of enrollment, with a stable or documented dose (no dose change within the 4 weeks prior to enrollment).
- Self-reported interest in supporting weight management, lean muscle maintenance, nutritional adequacy, or beauty-related benefits (e.g., skin, hair, nails) during GLP-1 therapy.
- Willing and able to use Glow Shakes Premium Collagen Meal Replacement as a once-daily meal replacement (replacing a typical meal) for 12 consecutive weeks and to complete all questionnaire assessments and Withings smart scale body composition measurements at Baseline, Week 4, Week 8, and Week 12.
- Willing and able to maintain current GLP-1 or dual-incretin medication dose throughout the study duration without planned dose adjustments (except in the event of a medically indicated change).
- Willing to maintain current diet (except for the study product), exercise routine, and lifestyle habits for the duration of the 12-week study, without introducing any new supplements or products specifically targeting weight loss, appetite, or body composition.
- In good general health.
- Resides in the United States.
Exclusion Criteria:
- Pregnant or breastfeeding at the time of enrollment, or planning to become pregnant during the 12-week study period.
- Known allergy or intolerance to any ingredient in the Glow Shakes formulation, including milk, whey, or collagen-derived ingredients.
- Diagnosed with a serious medical condition requiring medical nutritional management, including but not limited to Type 1 diabetes, active cancer, or severe renal or hepatic disease.
- Currently testing, or plan to in the next 12 weeks, a product for another research study.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Glow Shakes Premium Collagen Meal Replacement Arm
|
Participants will consume one serving once daily - replacing a typical meal such as breakfast or lunch - for 12 consecutive weeks. One serving is prepared by adding the powder to 11.8 fl oz (approximately 350 mL) of water: add water first, then two scoops of powder, and shake for fewer than 10 seconds. Drink immediately after preparation. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in Perceived Nutritional Adequacy
Tijdsspanne: Baseline to Week 12
|
Within-participant change in perceived nutritional adequacy assessed via self-report questionnaire |
Baseline to Week 12
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in Body Fat Percentage
Tijdsspanne: Baseline to Week 12
|
Within-participant change in body fat percentage (%) measured by participant self-administered Withings smart scale |
Baseline to Week 12
|
|
Change in Muscle Mass
Tijdsspanne: Baseline to Week 12
|
Within-participant change in muscle mass (kg) measured by participant self-administered Withings smart scale |
Baseline to Week 12
|
|
Change in Self-Reported Weight Management and Food Cravings
Tijdsspanne: Baseline to Week 12
|
Within-participant change assessed via the validated Food Cravings Questionnaire-Trait Reduced (FCQ-T-reduced) |
Baseline to Week 12
|
|
Change in Self-Reported Perceived Skin Smoothness
Tijdsspanne: Baseline to Week 12
|
Within-participant change in perceived skin smoothness score assessed via self-report questionnaire |
Baseline to Week 12
|
|
Change in Self-Reported Perceived Skin Elasticity
Tijdsspanne: Baseline to Week 12
|
Within-participant change in perceived skin elasticity score assessed via self-report questionnaire |
Baseline to Week 12
|
|
Change in Self-Reported Hunger Intensity
Tijdsspanne: Baseline to Week 12
|
Within-participant change in perceived hunger intensity assessed via visual analogue scale or equivalent validated hunger/satiety instrument |
Baseline to Week 12
|
|
Change in Self-Reported Satiety Duration
Tijdsspanne: Baseline to Week 12
|
Within-participant change in perceived satiety duration assessed via visual analogue scale or equivalent validated hunger/satiety instrument |
Baseline to Week 12
|
|
Change in Self-Reported Food Craving Scores
Tijdsspanne: Baseline to Week 12
|
Within-participant change in food craving scores assessed via the Food Cravings Questionnaire-Trait Reduced (FCQ-T-reduced) |
Baseline to Week 12
|
|
Change in Self-Reported Hair Thickness
Tijdsspanne: Baseline to Week 12
|
Within-participant change in perceived hair thickness assessed via self-report questionnaire |
Baseline to Week 12
|
|
Change in Self-Reported Hair Health
Tijdsspanne: Baseline to Week 12
|
Within-participant change in perceived hair health assessed via self-report questionnaire |
Baseline to Week 12
|
|
Change in Self-Reported Energy Levels
Tijdsspanne: Baseline to Week 12
|
Within-participant change in perceived energy levels assessed via self-report questionnaire |
Baseline to Week 12
|
|
Change in Self-Reported Cognitive Focus
Tijdsspanne: Baseline to Week 12
|
Within-participant change in perceived cognitive focus assessed via self-report questionnaire |
Baseline to Week 12
|
|
Change in Self-Reported Nail Thickness
Tijdsspanne: Baseline to Week 12
|
Within-participant change in perceived nail thickness assessed via self-report questionnaire |
Baseline to Week 12
|
|
Change in Self-Reported Nail Health
Tijdsspanne: Baseline to Week 12
|
Within-participant change in perceived nail health assessed via self-report questionnaire |
Baseline to Week 12
|
|
Change in Gut Comfort and Digestive Health
Tijdsspanne: Baseline to Week 12
|
Within-participant change in gut comfort and digestive symptom scores assessed via self-report questionnaire |
Baseline to Week 12
|
|
Change in Self-Reported Metabolism Support
Tijdsspanne: Baseline to Week 12
|
Within-participant change in perceived metabolism support assessed via self-report questionnaire |
Baseline to Week 12
|
|
Change in Self-Reported Physical Strength
Tijdsspanne: Baseline to Week 12
|
Within-participant change in perceived physical strength assessed via self-report questionnaire |
Baseline to Week 12
|
|
Product Tolerability and Participant Satisfaction
Tijdsspanne: Week 12
|
Participant-reported product satisfaction, acceptability, and tolerability assessed via product satisfaction questionnaire |
Week 12
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- THECO-73657
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .